Could you kindly introduce yourself and tell us a little bit about your position at Carcinotech?
Ishani Malhotra, CEO and creator of Carcinotech, has a Certificate of Achievement from Harvard Medical School and nine years of experience in stem cell and oncology research. She holds degrees from the University of Edinburgh. Before starting Carcinotech, she gained experience in the fields of oncology and stem cell research while working at Censo Biotechnologies, HCG Oncology hospitals, The Institute of Cytology and Preventative Oncology, and Stempeutics. She has won various accolades on national and international platforms and was featured as a Director of the Year Regional finalist at the Institute of Directors Scotland 2021 awards.
She was most recently named one of Scottish Business Insider’s 35 Rising Stars under 35. She won the Scottish SME Business Awards 2022 Female Entrepreneur of the Year award as well as the AccelerateHer 2022 Awards for Science and MedTech. To further Carcinotech’s goal of offering individualized medication testing platforms to patients with cancer, she has formed substantial international relationships. She collaborated with businesses and academic institutions, including Cancer Research UK and Cellink, to enhance the technology’s validation.
Ishani Malhotra launched Carcinotech in 2018 as a result of her study at the University of Edinburgh. To begin the firm’s entrepreneurial journey, Ishani won many business competitions and received grant financing from Scottish Enterprise. Grant-funded proof of concept and validation data allowed her to secure the initial capital needed to market this technology.
Personalized cancer treatments can be better understood by using 3D-printed tumor mimics, according to the startup Carcinotech. Can you give us some background on Carcinotech and describe some of your goals and missions?
A specialist in creating 3D-printed living tumors using patient-derived biopsies, primary cells, immune cells, and cancer stem cells is Carcinotech, a MedTech business. The cutting-edge models developed by Carcinotech offer a platform for quick, ethical, and precise drug screening as well as pre-clinical and individualized medicine testing.
In order to improve each cancer patient’s likelihood of receiving treatment and surviving, Carcinotech’s aim is to be at the forefront of cancer drug testing and offer individualized medicine testing.
At Carcinotech, we use technology to lessen and eventually do away with the need for animal testing when developing new drugs. We create humanized models to address one of the largest problems the pharmaceutical industry is now facing: the use of animal testing.
Carcinotech seeks to democratize cancer therapy by accelerating the release of superior medications. Ishani set out to tackle the main issues facing the cancer industry, such as reproducing the immune and tumor microenvironments in patients. Our response to this problem is the immuno-oncology-focused printed tumors created by Carcinotech using the patient’s immune cells. Traditional organoid models are less reproducible, need up to 90 days to be assay-ready, and cannot be used with high-throughput systems. This issue is resolved by Carcinotech’s 3D-printed tumors, which produce tumors quickly and consistently in high-throughput formats.
Although personalized medicine has come a long way in recent years, there are still several obstacles to overcome before it becomes widely used in clinical settings. What do you think are the main obstacles to the practice of personalized medicine, and how is Carcinotech attempting to overcome them?
Adoption of technology – Inform people about the advantages, characteristics, and fundamentals of personalized medicine
Further research is required, and our work helps advance the field of customized medicine and its applications.
more costly than the standard “one drug works for all” remedies
Carcinotech creates 3D-printed live tumors from biopsies and patient-derived cells. Can you provide us with further information about your models, their creation, and their potential application to testing for personalized medicine?
For brain, lung, breast, colorectal, and ovarian cancers with known patient populations and mutational status, we have created patient-specific printed tumors. Our adaptable technique enables us to create models for any solid tumors in addition to the five malignancies. For all types of cancer, particularly uncommon malignancies, we continually create new products.
Using our unique ECM, which replicates the original tumor environment, we print each tumor. Our models take into account the immune cells present in each patient’s tumor as well as its heterogeneity.
The technology developed by Carcinotech has the potential to transform cancer research by giving surgeons and oncologists the ability to test prospective therapies, gauge how well they work against cancer, and develop individualized treatment plans for each patient.
What advantages do patients and therapeutic settings gain from adopting these 3D-printed models?
Rapid results enable the creation of more precise and timely treatment strategies.
Allow for individualized treatment strategies; like every person’s body is unique, so is every person’s cancer. To better meet each patient’s unique demands, this necessitates a customized treatment approach. Our 3D-printed tumors will enable surgeons to select the most effective course of treatment for each patient’s cancer, enhancing their access to treatment, quality of life, and survival chances.
These models are credited with “reinventing” the field of cancer research. How is that?
Modern therapies will be made possible thanks to our technologies.
Carcinotech’s product line is exceptional. Thousands of companies are making great efforts to upgrade their technologies in order to provide better options for manufacturing, medicine development, and cancer research. The only company in our sector using 3D-printed living tumors is Carcinotech. The majority of our rivals use 2D models, which are not accurate representations of actual living tumors within a patient. Therefore, because our 3D-printed tumors are much closer to the patient’s biopsies, our technique enables more reliable drug screening/testing results.
You presently work closely with CELLINK, a renowned bioprinting company, in a number of partnerships to hasten the introduction of novel, effective cancer treatments. How crucial are these partnerships in launching novel therapeutics?
Every collaboration they offer is valued by us… Our collaboration with CELLINK has given us access to their cutting-edge 3D bioprinters and bioinks, advancing the advancement of our technology.
Additionally, as part of a beta test, we provided certain GBM models to Cancer Research UK. This gave us the chance to enhance our product so that it better-suited drug testing researchers.
Dollar General was once more found to be in breach of federal workplace safety regulations for having blocked emergency exits and “dangerous” fire hazards.
These kinds of partnerships make it possible for smaller biotech firms like ours to develop and market our technology more quickly, boosting the number of innovative treatments that reach the market and advancing cancer research and drug development as a whole.
By pooling resources and expertise with other organizations that share our values, we can more quickly achieve our corporate objectives and mission while also advancing society as a whole.
What will Carcinotech do next? Do you have any upcoming projects that sound exciting?
Carcinotech is currently prepared to explore fresh foreign markets. We’re concentrating on entering the US market with our advanced product in 2023, and we’ve already started talking to potential customers about it. Along with expanding operations domestically in the UK and Europe, this market will be a significant source of income for the corporation.
Concerning Ishani Malhotra
Ishani Malhotra, CEO and creator of Carcinotech, has a Certificate of Achievement from Harvard Medical School and nine years of experience in stem cell and oncology research. She holds degrees from the University of Edinburgh.
Long-COVID prevalence among English schoolchildren: Research indicates extensive effects on health and wellbeing
Ishani correctly identified a little child with leukemia ten years ago, but she was aware that he would not be able to receive the cutting-edge treatment he needed throughout his life because it would take 10-15 years to reach the market. By 2030, the WHO predicts that there will be 22 million new instances of cancer worldwide. As a result, millions of people will miss out on cutting-edge treatments due of inefficient, expensive, and out-of-date methods employed in the production of pharmaceuticals. Ishani sought to create a technique that would specifically address this issue so that cancer therapies could hit the market more quickly and make cutting-edge treatments accessible to everyone.